Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Whitehawk Therapeutics (WHWK) Gross Margin (2021 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Gross Margin for 5 consecutive years, with 89.36% as the latest value for Q1 2025.

  • On a quarterly basis, Gross Margin rose 154.0% to 89.36% in Q1 2025 year-over-year; TTM through Sep 2025 was 89.22%, a 183.0% increase, with the full-year FY2024 number at 88.36%, down 10.0% from a year prior.
  • Gross Margin was 89.36% for Q1 2025 at Whitehawk Therapeutics, roughly flat from 89.09% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 100.0% in Q4 2021 to a low of 85.35% in Q4 2023.
  • A 5-year average of 90.05% and a median of 89.23% in 2024 define the central range for Gross Margin.
  • Peak YoY movement for Gross Margin: plummeted -1041bps in 2023, then soared 374bps in 2024.
  • Whitehawk Therapeutics' Gross Margin stood at 100.0% in 2021, then decreased by -4bps to 95.75% in 2022, then fell by -11bps to 85.35% in 2023, then rose by 4bps to 89.09% in 2024, then rose by 0bps to 89.36% in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Gross Margin are 89.36% (Q1 2025), 89.09% (Q4 2024), and 88.85% (Q3 2024).